Business
Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress
SAN DIEGO, May 07, 2026--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced its financial results for the quarter ended March 31, 2026, and provided corporate updates.
About this update from Arcturus Therapeutics Holdings Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":3600,"height":1320,"url":"https://media.zenfs.com/en/business-wire.com/427aab299d03790539603951090ba1c2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cYxK0lK43shsqs94HUALig--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM1Mg--/https://media.zenfs.com/en/business-wire.com/427aab299d03790539603951090ba1c2","width":960,"height":352},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/D1n5qKiZceTjeXM4xVhe6w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTIzNQ--/https://media.zenfs.com/en/business-wire.com/427aab299d03790539603951090ba1c2","width":640,"height":235},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/hZFyWDmIAZdlAIGwfHScyA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04ODA-/https://media.zenfs.com/en/business-wire.com/427aab299d03790539603951090ba1c2","width":1200,"height":440}},"lazy":false},{"type":"text","content":"Initiated enrollment (Q1 2026) earlier than expected for 12‑week cystic fibrosis (CF) open label Phase 2 study; lung function (ppFEV1 and LCI) is being monitored in Class I CF subjects","length":184,"tagName":"p","attribs":{}},{"type":"text","content":"Received regulatory direction on pediatric development strategy from FDA (Type C meeting) for ornithine transcarbamylase (OTC) deficiency program; End of Phase 2 (EOP2) meeting H2 2026","length":184,"tagName":"p","attribs":{}},{"type":"text","content":"Investor conference call at 4:30 p.m. ET today","length":46,"tagName":"p","attribs":{}},{"type":"text","content":"SAN DIEGO, May 07, 2026--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced its financial results for the quarter ended March 31, 2026, and provided corporate updates.","length":361,"tagName":"p"},{"type":"text","content":""Arcturus continues to advance its rare disease therapeutics portfolio. We have initiated enrollment of our 12‑week CF Phase 2 study in the first quarter of 2026, earlier than originally anticipated. We remain committed to advancing our inhaled mRNA therapy for people with CF Class I mutations," said Joseph Payne, President & CEO of Arcturus. "Also, during the f...